Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation

Dual antiplatelet therapy (DAPT) with aspirin and P2Y(12) inhibitor is administered following percutaneous coronary intervention (PCI) with coronary stent implantation. Several studies have reported the effects of switching between P2Y(12) inhibitors on platelet reactivity (P2Y(12) reaction units: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimamatsu, Junichiro, Sasaki, Ken-ichiro, Katsuki, Yoshio, Kawasaki, Tomohiro, Murasato, Yoshinobu, Ajisaka, Hidehiko, Yokoi, Hiroyoshi, Tashiro, Hideki, Harada, Atsushi, Hirakawa, Yuji, Ishizaki, Yuta, Ishimatsu, Takashi, Kagiyama, Kotaro, Fukumoto, Yoshihiro, Kakuma, Tatsuyuki, Ueno, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026273/
https://www.ncbi.nlm.nih.gov/pubmed/31549178
http://dx.doi.org/10.1007/s00380-019-01499-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026273/
https://www.ncbi.nlm.nih.gov/pubmed/31549178
http://dx.doi.org/10.1007/s00380-019-01499-7

Ejemplares similares